Home > Cardiology > ACC 2022 > Prevention > TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen

TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen

Presented By
Dr Brian Bergmark, Brigham and Women’s Hospital, USA
Conference
ACC 2022
Trial
Phase 2, TRANSLATE-TIMI 70
Doi
https://doi.org/10.55788/0fc9ff03
Vupanorsen, an investigational angiopoietin-like protein 3 (ANGPTL3) inhibitor, reduced non-high-density lipoprotein (non-HDL) cholesterol levels in patients with elevated cholesterol who were treated with statins. However, injection site reactions and elevated levels of liver enzymes were common and increased with dose.  The multicentre, double-blind, placebo-controlled, phase 2b TRANSLATE-TIMI 70 trial (NCT04516291) randomised 286 patients with non-HDL cholesterol levels ≥100 mg/dL and triglyceride levels of 150 to 500 mg/dL who were treated with statins to subcutaneous vupanorsen (80, 120, or 160 mg every 4 weeks; 60, 80, 120, or 160 mg every 2 weeks) or placebo (n=44) [1]. The primary endpoint was the placebo-adjusted percentage change from baseline in non-HDL cholesterol at week 24. Dr Brian Bergmark (Brigham and Women’s Hospital, MA, USA) pre...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on